Insider Selling: Beigene, Ltd. (NASDAQ:ONC) Insider Sells $9,333,360.00 in Stock

Beigene, Ltd. (NASDAQ:ONC) insider Xiaodong Wang sold 41,760 shares of Beigene stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $223.50, for a total transaction of $9,333,360.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Xiaodong Wang also recently made the following trade(s):

• On Monday, April 14th, Xiaodong Wang sold 41,760 shares of Beigene stock. The shares were sold at an average price of $242.66, for a total transaction of $10,133,481.60.
• On Tuesday, March 18th, Xiaodong Wang sold 41,760 shares of Beigene stock. The shares were sold at an average price of $261.28, for a total transaction of $10,911,052.80.
• On Tuesday, March 4th, Xiaodong Wang sold 8,146 shares of Beigene stock. The shares were sold at an average price of $254.58, for a total transaction of $2,073,808.68.

Beigene Stock Performance

ONC stock opened at $228.38 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. Beigene, Ltd. has a one year low of $141.31 and a one year high of $287.88. The business’s 50 day simple moving average is $243.42. The stock has a market capitalization of $22.62 billion, a P/E ratio of -27.72, a PEG ratio of 7.73 and a beta of 0.35.

Beigene (NASDAQ:ONC) last issued its earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of ($0.71) by $1.93. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.12 billion. On average, research analysts predict that Beigene, Ltd. will post -5.82 EPS for the current year.

Analyst Upgrades and Downgrades

ONC has been the subject of several research analyst reports. TD Securities reiterated a “buy” rating and set a $334.00 target price on shares of Beigene in a research report on Thursday, April 24th. JMP Securities set a $348.00 price target on shares of Beigene in a research note on Friday, February 28th. Guggenheim lifted their price target on shares of Beigene from $348.00 to $350.00 and gave the stock a “buy” rating in a research note on Thursday, May 8th. Sanford C. Bernstein set a $259.00 price target on shares of Beigene in a research note on Thursday, March 13th. Finally, Macquarie lifted their price target on shares of Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Beigene has a consensus rating of “Buy” and a consensus price target of $319.00.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.